Consequently, the developments in transdermal delivery systems for Tadalafil are a shift in the management of erectile dysfunction and benign prostatic hyperplasia. The main disadvantages of conventional oral formulations are poor absorption, first-pass metabolism, and a number of side effects that may compromise patient compliance. Nonetheless, there are drawbacks associated with these formulation types, which have been overcome to a large extent by transdermal formulations such as patches and formulations at the nano scale. It has also reduced the bioavailability and steady state drug concentrations than that of transdermal Tadalafil, which increases the therapeutic efficacy. Further, the slow and sustained release typical of transdermal delivery has been linked to lessened system toxicities, thus improving patient compliance. Research work has also started to support these innovations and the potential of the transdermal Tadalafil in offering better results than the oral Tadalafil has been proved. Further studies are being conducted on the ways to improve the efficiency of Tadalafil administration, and all of them show a positive trend in this regard. As the methods of transdermal drug delivery develop all over the world, the possibility to enhance the usage of Tadalafil for patients can be seen. This shift is not only expected to increase the effectiveness of therapy but also to increase the general quality of life of patients. Subsequent studies will also be required to determine uniform transdermal formulations and elaborate on therapeutic possibilities in uncommon patient groups. Transdermal Tadalafil can be considered a new moving step in the search for which the most adequate therapeutic solution for erectile dysfunction may exist.